2. Search Result
Search Result
Results for "

glutamate+transporter

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Peptides

1

Recombinant Proteins

2

Isotope-Labeled Compounds

6

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1190
    Cefadroxil
    5 Publications Verification

    BL-S 578

    		 Bacterial Antibiotic EAAT Infection Neurological Disease
    Cefadroxil is an orally active broad-spectrum cephalosporin antibiotic. Cefadroxil inhibits bacterial cell wall synthesis and enhances the expression of glutamate transporter-1. Cefadroxil is dependent on the intestinal peptide transporter PepT1 for small intestinal absorption. Cefadroxil has inhibitory and bactericidal activity against a variety of Gram-positive and Gram-negative bacteria and has analgesic effects on neuropathic pain .
    Cefadroxil
  • HY-100784
    Dihydrokainic acid
    1 Publications Verification

    		 EAAT Neurological Disease
    Dihydrokainic acid is a glutamate transporters (especially GLT1) inhibitor. Dihydrokainic acid targets GLT1 with high affinity, effectively inhibiting its transport function. Dihydrokainic acid exerts its effect by inhibiting the uptake of glutamate, leading to an increase in extracellular glutamate concentration, thereby affecting neuronal excitability and neurotransmission. Dihydrokainic acid is mainly applied in the field of neuroscience for research on glutamate-related neural functions, epilepsy, learning, and memory .
    Dihydrokainic acid
  • HY-139087
    Erastin2
    5 Publications Verification

    		 Ferroptosis Metabolic Disease
    Erastin2, an Erastin (HY-15763) analog, is a ferroptosis inducer and a potent, selective inhibitor of the system xc(-) cystine/glutamate transporter
    Erastin2
  • HY-Y1147
    Diethyl maleate
    1 Publications Verification

    Maleic acid diethyl ester

    		 Biochemical Assay Reagents Others
    Diethyl maleate (DEM) is an orally available, effective glutathione (GSH) depletor that crosses the blood-brain barrier. Diethyl maleate covalently binds irreversibly to GSH via glutathione S-transferase with an in vitro IC50 of 0.1-0.5 mM. Diethyl maleate selectively depletes GSH in liver, lung, and brain tissues, exacerbating oxidative stress and enhancing hyperbaric oxygen toxicity. Diethyl maleate promotes precursor amino acid uptake and in turn promotes GSH synthesis by upregulating the activity of the cystine-glutamate transporter XO -. Diethyl maleate can be used to study redox homeostasis and GSH protection mechanisms in oxidative stress-related diseases such as hyperbaric oxygen injury and metabolic diseases[1][2][3].
    Diethyl maleate
  • HY-107661
    Arundic Acid
    2 Publications Verification

    ONO-2506; (R)-2-Propyloctanoic acid

    		 ERK Akt NF-κB EAAT Cardiovascular Disease Neurological Disease
    Arundic Acid is an orally effective astrocyte function modulator and neuroprotective agent. Arundic Acid increases the expression and function of the astrocytic glutamate transporter EAAT1 by activating the ERK, Akt and NF-κB pathways. Arundic Acid attenuates retinal ganglion cell death in a normal-tension glaucoma model. Arundic Acid exerts neuroprotective effects in a mouse model of Parkinson's disease. Arundic Acid is a S100β protein synthesis inhibitor that prevents neurological deficits and brain tissue damage after intracerebral hemorrhage in rats. Arundic Acid downregulates neuroinflammation and astrocytic dysfunction after status epilepticus in immature rats. Arundic Acid is applicable to research related to Parkinson's disease, cerebral ischemia, glaucoma, intracerebral hemorrhage and epilepsy .
    Arundic Acid
  • HY-12741
    LDN-212320
    Maximum Cited Publications
    9 Publications Verification

    LDN-0212320; OSU-0212320

    		 EAAT Neurological Disease
    LDN-212320 (LDN-0212320) is a glutamate transporter (GLT-1)/excitatory amino acid transporter 2 (EAAT2) activator (at translational level). LDN-212320 (LDN-0212320) prevents nociceptive pain by upregulating astroglial GLT-1 expression in the hippocampus and ACC [1]
    LDN-212320
  • HY-107521
    TFB-TBOA
    3 Publications Verification

    CF3-Bza-TBOA

    		 EAAT Neurological Disease
    TFB-TBOA (CF3-Bza-TBOA) is a potent glutamate transporter blocker that potently suppresses the activity of glial transporters. TFB-TBOA shows IC50 values of 22, 17, and 300 nM for glutamate transporters EAAT1, EAAT2, and EAAT3 respectively in an uptake assay using cells transiently expressing EAATs .
    TFB-TBOA
  • HY-B1190A
    Cefadroxil hydrate
    5 Publications Verification

    BL-S 578 hydrate

    		 Bacterial Antibiotic EAAT Infection Neurological Disease
    Cefadroxil hydrate is an orally active broad-spectrum cephalosporin antibiotic. Cefadroxil hydrate inhibits bacterial cell wall synthesis and enhances the expression of glutamate transporter-1. Cefadroxil hydrate is dependent on the intestinal peptide transporter PepT1 for small intestinal absorption. Cefadroxil hydrate has inhibitory and bactericidal activity against a variety of Gram-positive and Gram-negative bacteria and has analgesic effects on neuropathic pain .
    Cefadroxil hydrate
  • HY-124619
    GPI-1046

    		EAAT HIV Neurological Disease
    GPI-1046 is an orally active, antibiotic-free immunophilin ligand that reduces ethanol intake by upregulating glutamate transporter 1 (GLT1) in the prefrontal cortex (PFC) and nucleus accumbens core (NAc-core). GPI-1046 improves human immunodeficiency virus (HIV)-associated sensory neuropathy (HIV-SN) by attenuating store-operated calcium (SOC) entry. GPI-1046 has neuroprotective activity .
    GPI-1046
  • HY-21045
    5-Fluoro-L-tryptophan

    L-5-Fluorotryptophan

    		 EAAT Neurological Disease
    5-Fluoro-L-tryptophan is a competitive vesicular glutamate transporter (VGLUT) inhibitor. 5-Fluoro-L-tryptophan is promising for research of diseases associated with the neurotransmitter systems .
    5-Fluoro-L-tryptophan
  • HY-139692
    EAAT2 activator 1

    		EAAT Neurological Disease
    EAAT2 activator 1 is the potent activator of excitatory amino acid transporter 2 (EAAT2). EAAT2 is the major glutamate transporter and functions to remove glutamate from synapses. EAAT2 activator 1 increases EAAT2 protein levels dose-dependently .
    EAAT2 activator 1
  • HY-100836
    trans-4-Carboxy-L-proline

    		iGluR Neurological Disease
    Trans-4-Carboxy-L-prolineis a selective glutamate transporter inhibitor .
    trans-4-Carboxy-L-proline
  • HY-W585874
    Nε-(Carboxyethyl)lysine

    		EAAT Apoptosis Neurological Disease Metabolic Disease
    Nε-(Carboxyethyl) lysine is an advanced glycation end product (AGE). Nε-(Carboxyethyl) lysine induces cross-linking between proteins, thereby affecting protein structure and function and causing protein denaturation. Nε-(Carboxyethyl) lysine binds to the RAGE receptor, affects cell signal transduction, and regulates processes such as inflammatory responses, cell proliferation, and apoptosis. Nε-(Carboxyethyl) lysine affects glutamate transporters, reduces glutamate uptake and S100β protein secretion, influences neurotransmission in the nervous system, and exhibits diabetes-related neurotoxicity .
    Nε-(Carboxyethyl)lysine
  • HY-133177
    MS-153

    		EAAT Neurological Disease
    MS-153 is a glutamate transporter activator that can be used as a neuroprotective agent .
    MS-153
  • HY-B1190R
    Cefadroxil (Standard)

    BL-S 578 (Standard)

    		 Reference Standards Bacterial Antibiotic EAAT Infection Neurological Disease
    Cefadroxil (Standard) is the analytical standard of Cefadroxil (HY-B1190). This product is intended for research and analytical applications. Cefadroxil is an orally active broad-spectrum cephalosporin antibiotic. Cefadroxil inhibits bacterial cell wall synthesis and enhances the expression of glutamate transporter-1. Cefadroxil is dependent on the intestinal peptide transporter PepT1 for small intestinal absorption. Cefadroxil has inhibitory and bactericidal activity against a variety of Gram-positive and Gram-negative bacteria and has analgesic effects on neuropathic pain .
    Cefadroxil (Standard)
  • HY-B1190S
    Cefadroxil-d4 hydrate

    BL-S 578-d4 hydrate

    		 Isotope-Labeled Compounds Bacterial Antibiotic EAAT Infection Neurological Disease
    Cefadroxil-d4 (hydrate) is the deuterium labeled Cefadroxil hydrate (HY-B1190A). Cefadroxil hydrate is an orally active broad-spectrum cephalosporin antibiotic. Cefadroxil hydrate inhibits bacterial cell wall synthesis and enhances the expression of glutamate transporter-1. Cefadroxil hydrate is dependent on the intestinal peptide transporter PepT1 for small intestinal absorption. Cefadroxil hydrate has inhibitory and bactericidal activity against a variety of Gram-positive and Gram-negative bacteria and has analgesic effects on neuropathic pain .
    Cefadroxil-d4 hydrate
  • HY-101334
    MPDC

    		GlyT Neurological Disease
    MPDC is a potent and competitive inhibitor of the Na +-dependent high-affinity glutamate transporter in forebrain synaptosomes .
    MPDC
  • HY-101334A
    MPDC hydrochloride

    		GlyT Neurological Disease
    MPDC hydrochloride is a potent and competitive inhibitor of the Na +-dependent high-affinity glutamate transporter in forebrain synaptosomes .
    MPDC hydrochloride
  • HY-100616
    cis-ACBD

    cis-1-Aminocyclobutane-1,3-dicarboxylic acid

    		 Sodium Channel Neurological Disease
    cis-ACBD is a potent and selective inhibitor of the high-affinity, Na +-dependent plasma membrane glutamate transporter. cis-ACBD is a glutamate reuptake inhibitor. cis-ACBD also acts as linear competitive inhibitor of the uptake of D-[3H]aspartate .
    cis-ACBD
  • HY-100784R
    Dihydrokainic acid (Standard)

    		Reference Standards EAAT Neurological Disease
    Dihydrokainic acid (Standard) is the analytical standard of Dihydrokainic acid. This product is intended for research and analytical applications. Dihydrokainic acid (DHK) is a glutamate transporter GLT1 (EAAT2) inhibitor. Dihydrokainic acid impairs novel object recognition (NOR) memory performance in mice. Dihydrokainic acid also shows epileptogenic effects .
    Dihydrokainic acid (Standard)
  • HY-100838
    cis-α-(Carboxycyclopropyl)glycine

    L-CCG III

    		 EAAT Neurological Disease
    cis-α-(Carboxycyclopropyl)glycine (L-CCG III) is a potent, competitive glutamate uptake inhibitor. cis-α-(Carboxycyclopropyl)glycine is a substrate of glutamate transporters (GluT) (EC50: 13 μM, 2 μM for EAAT 1 and EAAT 2, respectively). cis-α-(Carboxycyclopropyl)glycine inhibits a Na +-dependent high-affinity L-glutamate uptake in glial plasmalemmal vesicles (GPV) and synaptosomes .
    cis-α-(Carboxycyclopropyl)glycine
  • HY-B1190S2
    Cefadroxil-13C6

    BL-S 578-13C6

    		 Isotope-Labeled Compounds Bacterial Antibiotic EAAT Infection Neurological Disease
    Cefadroxil- 13C6 (BL-S 578- 13C6) is 13C labeled Cefadroxil (HY-B1190). Cefadroxil is an orally active broad-spectrum cephalosporin antibiotic. Cefadroxil inhibits bacterial cell wall synthesis and enhances the expression of glutamate transporter-1. Cefadroxil is dependent on the intestinal peptide transporter PepT1 for small intestinal absorption. Cefadroxil has inhibitory and bactericidal activity against a variety of Gram-positive and Gram-negative bacteria and has analgesic effects on neuropathic pain .
    Cefadroxil-13C6
  • HY-182067
    anti-TNBC agent-15

    		Reactive Oxygen Species (ROS) Apoptosis Ferroptosis Cancer
    anti-TNBC agent-15 is a platinum (IV) complex with anti-triple-negative breast cancer activity. anti-TNBC agent-15 inhibits cancer cell viability. anti-TNBC agent-15 reverses the resistance of triple-negative breast cancer cells to Cisplatin (HY-17394), increases intracellular uptake, and effectively triggers apoptosis by inducing DNA damage, enhancing intracellular ROS accumulation and activating the mitochondrial pathway. anti-TNBC agent-15 enhances lipid peroxidation, interferes with the signal transduction of the cystine/glutamate transporter-glutathione peroxidase axis, and induces ferroptosis. anti-TNBC agent-15 significantly inhibits tumor growth in triple-negative breast cancer/Cisplatin xenograft models. anti-TNBC agent-15 can be used for the research of triple-negative breast cancer .
    anti-TNBC agent-15

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: